The latest announcements from Crassula Pharmaceuticals—science-driven breakthroughs, partnerships, and regulatory milestones. Assets and spokespeople are available for accredited media.
Happy Diwali from all of us at Crassula Pharmaceuticals. May this Festival of Lights bring renewed energy, health, and prosperity to every home. As we celebrate illumination in all its forms, we remain committed to advancing science and wellness—with the same spirit of clarity and purpose that Diwali inspires. ✨ Wishing you a bright, safe, and joyous Diwali.
Season’s Greetings from Crassula As we wrap up another year of delivering quality solutions and forging new horizons in the health and wellness sector, we want to express our heartfelt appreciation for our clients, partners, and community who have entrusted us with their well-being. This holiday season, we are filled with gratitude for every milestone reached and every partnership formed.
On this special day, we join in celebrating India’s 78th Independence Day, honoring the resilience, unity, and unwavering spirit of its people. As we commemorate the journey to freedom, let us continue striving for progress and prosperity. Wishing everyone a day filled with pride and reflection. Happy Independence Day! 🇮🇳
Crassula Launches Vascutan Plus, Irbesartan/Hydrochlorothiazide, in Honduras Tegucigalpa, Honduras – Continuing its commitment to cardiovascular health, Crassula Pharmaceuticals is proud to announce the release of Vascutan Plus, a combination medication containing Irbesartan and Hydrochlorothiazide, in Honduras. This new addition enhances Crassula’s portfolio by offering a comprehensive treatment solution for hypertension. Vascutan Plus combines Irbesartan, an angiotensin II receptor blocker (ARB),
Crassula Introduces Vascutan for Advanced Hypertension Control in Honduras Tegucigalpa, Honduras – Crassula Pharmaceuticals, a leader in cardiovascular healthcare solutions, is thrilled to announce the market introduction of Vascutan, an Irbesartan-based medication, in Honduras. This strategic expansion of Crassula’s cardiovascular portfolio underscores the company’s commitment to combating hypertension and associated cardiac conditions. Irbesartan, the active ingredient in Vascutan, is a
We are proud to announce a new addition to our team at CRASSULA! We are thrilled to announce an exciting new addition to our team at CRASSULA! Please join us in welcoming Daniel Suazo as the new Medical Representative Lead at #CrassulaHonduras. Daniel comes to us with an impressive background in the healthcare sector, where he has consistently demonstrated exceptional
Introducing Glycedil: Revolutionizing Type 2 Diabetes Management in Honduras Crassula Honduras Announces the Launch of Glycedil, Sitagliptin 100mg, in Honduras Tegucigalpa, Honduras – In a significant expansion of its diabetes care portfolio, Crassula Pharmaceuticals proudly introduces Glycedil, a Sitagliptin 100mg tablet, to the Honduran market. This strategic launch underscores Crassula’s unwavering commitment to innovating in the field of chronic disease
Crassula Launches Relixib, Etoricoxib 120mg Coated Tablet, in Honduras Crassula Pharmaceuticals Launches Relixib, Etoricoxib 120mg, in Honduras Tegucigalpa, Honduras – Crassula Honduras, a leading pharmaceutical manufacturer renowned for its commitment to quality, is excited to announce the introduction of Relixib, an etoricoxib 120mg tablet, to the Honduran market. This new addition to Crassula’s portfolio reinforces the company’s dedication to providing
Crassula Pharmaceuticals Welcomes Crassula is thrilled to announce the appointment of Dr. Bhavana Gupta as its new Chief Technical Officer (CTO). Dr. Gupta will be at the forefront of managing the technical operations of the company, including overseeing the research and development department. Her role will also encompass serving as a vital technical advisor, directly reporting to Mr. Roopesh Gupta,